Beijing – Zhu Tao, Chief Scientific Officer of CanSino Biologics and a member of the National Committee of the Chinese People’s Political Consultative Conference (CPPCC), is advocating for a significant expansion of China’s immunization planning system. His proposals, presented during the 2026 National Two Sessions, center on a comprehensive, full-lifecycle approach to vaccination, coupled with a national mechanism to address adverse reactions to vaccines. This push comes as China seeks to bolster public health and economic stability through preventative healthcare measures.
Zhu Tao’s recommendations focus on integrating medical and preventative care to create a more robust immunization framework. He highlighted the current low vaccination rates for key illnesses among adults, signaling a critical need for improvement. The proposals aim to move beyond traditional infant and childhood immunization schedules, extending protection to adolescents and adults throughout their lives. This comprehensive strategy is intended to reduce the overall burden of disease and associated healthcare costs.
Expanding Vaccine Coverage Across All Age Groups
Data presented by Zhu Tao reveals concerningly low vaccination rates in China. According to his findings, influenza vaccination among adults aged 18-59 stands at just 0.52%, while coverage for those 60 and above is less than 10%. Vaccination rates for pneumococcal and herpes zoster vaccines are even lower, presenting a significant public health challenge. These figures underscore the urgency of expanding access and promoting awareness of the benefits of vaccination across all demographics. He suggests prioritizing high-risk groups, such as school-aged children and elderly individuals with chronic conditions, for inclusion in phased local immunization plans.
Zhu Tao’s advocacy aligns with a broader national effort to strengthen preventative healthcare. Increasing vaccination rates isn’t solely a health issue, he argues, but also a crucial economic one. Investing in prevention can significantly reduce the long-term costs associated with treating preventable diseases. This perspective resonates with a growing understanding of the economic benefits of public health initiatives.
Addressing Adverse Reactions with a National Compensation System
Alongside the call for expanded immunization, Zhu Tao emphasized the need for a standardized, national-level compensation mechanism for individuals experiencing adverse reactions to vaccinations. Currently, addressing these reactions can be a complex and inconsistent process. A streamlined, nationwide system would provide greater clarity, support and fairness for those affected, potentially increasing public confidence in vaccines. He recommends speeding up the establishment of this long-term mechanism.
CanSino Biologics, under Zhu Tao’s leadership, has been at the forefront of vaccine innovation in China. The company’s Convidecia, a single-dose adenovirus-based viral vector vaccine for COVID-19, was listed by the World Health Organization for emergency use as reported in China Daily. The company is also exploring innovative delivery methods, including inhaled vaccines, aiming to make vaccination more accessible and less intimidating for those with a fear of needles.
AI and the Future of Vaccine Development
Zhu Tao also highlighted the transformative potential of artificial intelligence (AI) in the pharmaceutical industry, particularly in vaccine development. He believes AI is not merely a tool, but a “catalyst” accelerating research and development processes. From predicting protein structures to streamlining clinical report writing, AI is being integrated throughout the entire vaccine lifecycle. According to Futunn News, CanSino Biologics is already leveraging AI to optimize antigen design, improve protein expression efficiency, and even assist with clinical program writing and commercial promotion.
Zhu Tao, who also serves as a member of the CPPCC, has previously advocated for promoting Chinese vaccines internationally, particularly within countries along the Belt and Road Initiative as noted by Tsinghua University’s BRI EMBA program. This reflects a broader ambition for Chinese vaccine companies to contribute to global health security.
Looking ahead, the implementation of Zhu Tao’s proposals will require coordinated efforts between government agencies, healthcare providers, and pharmaceutical companies. The success of these initiatives will be crucial in strengthening China’s public health infrastructure and protecting its population from preventable diseases. The next key checkpoint will be the formal consideration of these proposals during the ongoing National Two Sessions and the subsequent development of concrete policy measures.
What are your thoughts on the proposed expansion of China’s immunization planning system? Share your comments below and join the conversation.
Disclaimer: This article provides informational content and should not be considered medical or public health advice. Consult with qualified healthcare professionals for personalized guidance.
